文献速递神经MR

无颅内异常成人患者增强MR成像后脑组织中的钆沉积

Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities.
PubMed 文献 · Radiology · 2017-06-27

研究对5例曾接受钆双胺增强MR检查(4–18次,2005–2014年)的无颅内异常成人尸检脑组织与10例从未暴露钆的对照者进行比较,采用ICP-MS、透射电镜及能谱分析和光镜检测。暴露组四个脑区组织钆含量为0.1–19.4 μg/g,呈显著剂量依赖关系(苍白球ρ=0.90,P=.04),对照组未检出钆。作者认为钆沉积可在血脑屏障通透性未受颅内病变影响时发生,对现有钆剂生物分布与安全性的认识提出挑战。

要点

  • 无颅内异常成人多次接受钆双胺增强MR后,尸检脑组织可检出钆沉积。
  • 沉积见于齿状核、脑桥、苍白球和丘脑,含量0.1–19.4 μg/g组织。
  • 沉积定位于毛细血管内皮和神经元间质,2例见于细胞核内。

核心结论

  • 钆双胺给药后神经组织钆沉积可发生于无颅内异常、血脑屏障通透性未受病变影响的患者。
  • 这些发现对现有钆对比剂生物分布及安全性的认识提出挑战。

研究设计与样本

  • 尸检病例对照研究,比较5例曾接受钆双胺增强MR检查者(2005–2014年间4–18次)与10例从未暴露钆者(一生中至少行1次MR检查)。
  • 取齿状核、脑桥、苍白球和丘脑组织,用ICP-MS定量、透射电镜及能谱分析定位、光镜评估沉积效应。
  • 已获生前知情同意及机构审查委员会批准。

关键影像表现/征象

  • 暴露组四个神经解剖区域组织钆含量为0.1–19.4 μg/g组织,呈统计学显著的剂量依赖关系(苍白球ρ=0.90,P=.04)。
  • 对照组ICP-MS未检出钆。
  • 所有患者尸检脑病理特征正常。
  • 暴露组钆沉积定位于毛细血管内皮和神经元间质,2例见于细胞核内。
  • 暴露组3例在MR检查时存在临界肾功能(估算肾小球滤过率<45 mL/min/1.73 m2)和肝胆功能障碍。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine whether gadolinium deposits in neural tissues of patients with intracranial abnormalities following intravenous gadolinium-based contrast agent (GBCA) exposure might be related to blood-brain barrier integrity by studying adult patients with normal brain pathologic characteristics. Materials and Methods After obtaining antemortem consent and institutional review board approval, the authors compared postmortem neuronal tissue samples from five patients who had undergone four to 18 gadolinium-enhanced magnetic resonance (MR) examinations between 2005 and 2014 (contrast group) with samples from 10 gadolinium-naive patients who had undergone at least one MR examination during their lifetime (control group). All patients in the contrast group had received gadodiamide. Neuronal tissues from the dentate nuclei, pons, globus pallidus, and thalamus were harvested and analyzed with inductively coupled plasma mass spectrometry (ICP-MS), transmission electron microscopy with energy-dispersive x-ray spectroscopy, and light microscopy to quantify, localize, and assess the effects of gadolinium deposition. Results Tissues from the four neuroanatomic regions of gadodiamide-exposed patients contained 0.1-19.4 μg of gadolinium per gram of tissue in a statistically significant dose-dependent relationship (globus pallidus: ρ = 0.90, P = .04). In contradistinction, patients in the control group had undetectable levels of gadolinium with ICP-MS. All patients had normal brain pathologic characteristics at autopsy. Three patients in the contrast group had borderline renal function (estimated glomerular filtration rate <45 mL/min/1.73 m2) and hepatobiliary dysfunction at MR examination. Gadolinium deposition in the contrast group was localized to the capillary endothelium and neuronal interstitium and, in two cases, within the nucleus of the cell. Conclusion Gadolinium deposition in neural tissues after GBCA administration occurs in the absence of intracranial abnormalities that might affect the permeability of the blood-brain barrier. These findings challenge current understanding of the biodistribution of these contrast agents and their safety. © RSNA, 2017.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. McDonald RJ, McDonald JS, Kallmes DF, et al. Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities. Radiology. 2017. PMID: 28653860. doi:10.1148/radiol.2017161595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。